Dr. Martin Hager, MBA
15
Seguidores
Personal Information
Organização/Local de trabalho
Basel Switzerland
Cargo
Oncology
Setor
Medical / Health Care / Pharmaceuticals
Marcadores
oncology
cancer
personalized healthcare
targeted therapy
big data in oncology
precision medicine
personalized medicine
ntrk inhibitor
ds-6051
dr. martin h. hager
treatment
comprehensive genomic profiling
artificial intelligence
therapy
venture capital
clinical trial
metastasis
tumor
cancer patients
personalised digital health interventions
eprom
rwd
kaiku health
tecentriq
digitale gesundheitsanwendung
diga
digital patient monitoring and management
decision support
pathology
mtb
cup-syndrom
clinical study
cupisco
cup
molecular tumor board
clinical decision support
cancer of unknown primary
tumor-agnostic
pan-tumor
astrazeneca
taletrectinib
ros1 inhibitor
pharmaceutical
daiichi-sankyo co. ltd.
digital
frankfurter allgemeine zeitung
strategy
digital pathology
digital strategy
big data
platform diagnostic
diagnostics
healthcare
oncology pipeline
genome
sequencing
profile
flatiron
foundation medicine
phc 2.0
phc
mba practicum
finance
germany
fundraising
history of capital markets
global
japan
stock market
economy
investment
capital markets
usa
seed financing
globalization
debt financing
fund performance
industry
entrepreneurship
mba
pharmaceuticals
big pharma
fostering leaders
leadership
angiogenesis
martin h. hager
department of defense
biomarker
prognostic
innovation
angel investor
peter hirth
arqule
nsclc
non-small cell lung cancer
daiichi sankyo
kinase inhibitor
mesenchymal amoeboid transition
amoeboid
emt
migration
epithelial mesenchymal transition
drf3
formin
plasticity
vemurafenib
plexxikon
ros1/ntrk inhibitor
dr. hager
daiichi-sankyo
daiichi sankyo co. ltd.
inhibitor
ntrk
translocation
ros1
Ver mais
- Apresentações
- Documentos
- Infográficos